ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO__________________ |
Title of each class |
Trading Symbol |
Name of each exchange on which registered | ||
(NASDAQ Global Select Market) |
☑ |
Accelerated filer ☐ |
Non-accelerated filer ☐ |
Smaller reporting company | |||
Emerging growth company |
Auditor Name: |
Auditor Location: |
Auditor Firm ID: |
Page |
||||||
4 | ||||||
ITEM 3. |
5 | |||||
ITEM 10. |
5 | |||||
ITEM 11. |
11 | |||||
ITEM 12. |
30 | |||||
ITEM 13. |
32 | |||||
ITEM 14. |
33 | |||||
ITEM 15. |
34 |
● |
Bryan Baldasare filed late Forms 4 on December 16, 2021 and December 22, 2021 to report the settlement of shares to cover certain taxes due upon vesting of units granted on November 8, 2017 and November 15, 2018, and November 4, 2021 and November 15, 2021, respectively. |
● |
Tony Serafini-Lamanna filed late Forms 4 on December 16, 2021 and October 5, 2022 to report the settlement of shares to cover certain taxes due upon vesting of units granted on November 15, 2018 and November 15, 2021, respectively. |
● |
Julie Smith filed a late Form 4 on October 5, 2022 to report the settlement of shares to cover certain taxes due upon vesting of units granted on September 16, 2019. |
● |
Lourdes Weltzien filed late Forms 4 on December 16, 2021 and December 22, 2021 to report the settlement of shares to cover certain taxes due upon vesting of units granted on November 8, 2017 and November 15, 2018, and November 4, 2021, respectively. |
● |
Reshape the financial profile to achieve higher growth over time, while maintaining strong financial returns and mitigating risks in our business. |
● |
Focus on organic and inorganic investment to re-allocate capital to where we can win and compete over the long-term. |
● |
Align the deployment of human capital and minimize risk, while improving organizational fitness. |
● |
Base salaries, which reflect job responsibilities, market competitiveness, and individual performance in connection with merit increases; |
● |
Annual cash-based incentive opportunities, which are a function of Company and personal performance; and |
● |
Longer-term stock-based incentive opportunities under our 2021 Omnibus Award Plan, in the form of stock options and restricted stock unit grants that vest over a minimum service period, and a new performance-based restricted stock unit program, which align the long-term interests of senior management with our shareholders. |
● |
The Company reported record consolidated net revenues of $333 million, up 5% year-over-year; |
● |
Diagnostics segment net revenues increased 22% year-over-year to $156 million, as its gastrointestinal and respiratory illness assays achieved 27% and 51% growth, respectively, reflecting the benefit of acquiring BreathTek ® in July 2021 and emerging from the midst of the COVID-19 pandemic; |
● |
Life Science segment net revenues decreased 7% year-over-year to $177 million, as the demand for COVID-19 related reagents declined during the last half of the fiscal year. However, Life Science segment net revenues were approximately 175% above the pre-pandemic levels of fiscal 2019; |
● |
The Company established a new Life Science segment recombinant protein R&D facility in New Jersey with assets acquired from EUPROTEIN Inc. in April 2022; and |
● |
The Company entered into an Agreement and Plan of Merger, which is expected to close on or before January 31, 2023. |
ORIGINAL TARGETS |
||||||||
Revenue Target (Millions) |
Non-GAAP Operating Income¹ Target (Millions) |
NEOs other than CEO |
CEO | |||||
Original Plan at Targets |
$300 | $65 | 55.0% | 95.0% | ||||
Original Plan Max Increments |
$ 20 | $ 5 | 16.5% | 28.5% | ||||
Original Plan Design Max Payout 2 |
$320 | $70 | 71.5% | 123.5% | ||||
Business Accelerator Additional Incentive |
$325 to $370 | NA | 3% to 33% | 6% to 57% | ||||
Individual Performance Additional Incentive |
>$340 | NA | 11% | 19% | ||||
Actual |
$333 | $76 | 91% | 169% |
Operating Income (GAAP to Non-GAAP Reconciliation) |
||||
U.S. GAAP operating income |
$ | 54,391,000 | ||
Litigation and select legal costs |
13,510,000 | |||
Acquisition and transaction related costs |
6,940,000 | |||
Restructuring costs |
1,109,000 | |||
Non-GAAP operating income for use in cash-based incentive target measurement |
$ | 75,950,000 | ||
Illustrative Performance Restricted Stock Units Payout Percentages¹ | ||||||
50% |
100% |
200% | ||||
Life Science Net revenues Net revenues growth |
$165,000,000 3.7% |
$175,000,000 10.0% |
$190,000,000 19.4% | |||
Diagnostics Net revenues Net revenues growth |
$165,000,000 1.9% |
$175,000,000 8.0% |
$190,000,000 17.3% | |||
Consolidated Net revenues Net revenues growth Non-GAAP operating income |
$330,000,000 2.8% $89,000 |
$350,000,000 9.0% $101,000 |
$380,000,000 18.3% $120,000 |
Life Science Net Revenues |
Diagnostics Net Revenues |
Consolidated Non-GAAP Operating Income Before Stock-Based Compensation Expense | ||||
Corporate functions |
40% | 40% | 20% | |||
Life Science segment |
80% | Not applicable | 20% | |||
Diagnostics segment |
Not applicable | 80% | 20% |
Fiscal 2022 |
||||
Base salaries CEO NEOs other than CEO Other executives |
No change No change 10% to 15% increases |
|||
CIP (annual cash-based incentive) CEO NEOs other than CEO Other executives |
Increase from 90% to 95% at Target Increase from 50% to 55% at Target 5-point increases at Target |
|||
Restricted Stock Unit vesting based on future employee service |
Change from 3-year cliff vesting to 4-year pro-rata vesting at 25% per year |
|||
Non-qualified stock option vestingbased on future employee service |
Change from 3-year cliff vesting to 4-year pro-rata vesting at 25% after the first yearand monthly thereafter |
|||
PSU award program |
Previously discussed herein |
Element |
Form of Compensation |
Purpose |
Risk Profile | |||
Base Salaries |
Cash | Provides competitive, fixed compensation to attract and retain exceptional executive talent | Low to moderate | |||
Annual Cash-Based Incentives |
Cash | Provides a direct financial incentive to achieve corporate operating goals | Moderate to high | |||
Long-Term Stock-Based Incentives |
Non-qualified stock options and/or restricted stock units, including performance-based awards |
Encourages executive officers to build and maintain a long-term equity ownership position in Meridian so that their interests are aligned with our shareholders | High | |||
Health, Retirement and Other Benefits |
Eligibility to participate in benefit plans generally available to our employees, including retirement plan contributions, and premiums paid on disability and life insurance policies | Benefit plans are part of a broad-based employee benefits program providing competitive benefits to our executive officers | Low | |||
Change in Control Severance Benefits |
Cash and continuation of certain benefits | Encourages executive officers to maximize value for shareholders in the event that the Company becomes subject to a change in control transaction | Moderate to high |
Name and Principal Position |
Year | Salary | Bonus 1 |
Stock Awards 2,3 |
Option Awards 4 |
Non-Equity Incentive Plan Compensation 5 |
Change in Pension Value and Nonqualified Deferred Compensation Earnings |
All Other Compensation 6 |
Total | |||||||||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | ||||||||||||||||||||||
Jack Kenny Chief Executive Officer |
|
2022 2021 2020 |
|
$ $ $ |
710,485 690,000 670,000 |
|
- - - |
$ $ $ |
1,954,684 1,035,000 1,005,000 |
|
|
$710,796 $690,000 $670,000 |
|
|
$1,200,000 $ 800,000 $ 958,770 |
|
- - - |
$ 22,860 $ 18,705 $ 26,714 |
$ $ $ |
4,598,825 3,233,705 3,330,484 |
| |||||||||
Andrew S. Kitzmiller 7 Executive Vice President, Chief Financial Officer |
2022 | $ | 226,539 | - | $ | 382,109 | $ 56,141 | $ 210,507 | - | $ 7,600 | $ | 882,896 | ||||||||||||||||||
Bryan T. Baldasare 8 Former Executive Vice President, Chief Financial Officer and Secretary |
|
2022 2021 2020 |
|
$ $ $ |
127,974 388,332 377,831 |
|
- - - |
$ $ $ |
200,000 200,000 201,028 |
|
|
$100,000 $100,000 - |
|
|
- $ 245,604 $ 290,016 |
|
- - - |
$ 13,506 $ 18,705 $ 33,749 |
$ $ $ |
441,480 952,641 902,624 |
| |||||||||
Lourdes G. Weltzien Executive Vice President, Life Science |
|
2022 2021 2020 |
|
$ $ $ |
396,862 383,847 368,711 |
|
- - - |
$ $ $ |
350,000 225,000 201,028 |
|
|
$100,000 $100,000 - |
|
|
$ 364,319 $ 263,106 $ 283,625 |
|
- - - |
$ 22,860 $ 18,705 $ 31,172 |
$ $ $ |
1,234,041 990,658 884,536 |
| |||||||||
Tony Serafini-Lamanna 9 Executive Vice President, Diagnostics |
|
2022 2021 2020 |
|
$ $ $ |
378,929 367,891 317,269 |
|
- - $30,000 |
$ $ $ |
350,000 200,000 120,613 |
|
|
$100,000 $100,000 $ 10,328 |
|
|
$ 347,856 $ 214,137 $ 274,752 |
|
- - - |
$ 22,601 $ 18,498 $ 32,979 |
$ $ $ |
1,199,386 900,526 785,941 |
| |||||||||
Julie Smith 10 Senior Vice President, Controller and Principal Accounting Officer |
|
2022 2021 2020 |
|
$ $ $ |
297,655 231,907 216,198 |
|
- - $15,000 |
$ $ $ |
247,750 99,995 60,306 |
|
|
- - $ 5,164 |
|
|
$ 218,151 $ 88,270 $ 103,500 |
|
- - - |
$ 22,860 $ 18,296 $ 23,057 |
$ $ $ |
786,416 438,468 423,225 |
|
Name | Grant Date |
Estimated Future Payouts Under Non- Equity Incentive Plan Awards 1 |
Estimated Future Payouts Under Equity Incentive Plan Awards 2 |
All other Stock Awards: Number of Shares of Stock or Units (#) |
All other Option Awards: Number of Securities Underlying Options (#) |
Exercise or Base Price of Option Awards ($/Sh) |
Grant Date Fair Value of Stock and Option Awards | ||||||||||||||||||||||||||||||||||||||||||||||||
Threshold ($) |
Target ($) |
Max ($) |
Threshold (#) |
Target (#) |
Max (#) |
||||||||||||||||||||||||||||||||||||||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | (k) | (l) | ||||||||||||||||||||||||||||||||||||||||||||
Jack Kenny 11 |
11/04/21 | $ | 135,053 | $ | 675,263 | $ | 1,688,157 | 23,530 | 47,060 | 94,120 | 56,472 | 5 |
82,940 | 6 |
$ | 8.57 | $ | 2,665,480 | |||||||||||||||||||||||||||||||||||||
Andrew S. Kitzmiller 3 |
02/21/22 | $ | 25,498 | $ | 127,490 | $ | 318,725 | 3,973 | 7,945 | 15,890 | 7,500 | 7 |
5,000 | 8 |
$ | 11.23 | $ | 438,250 | |||||||||||||||||||||||||||||||||||||
Bryan T. Baldasare 11 |
11/04/21 | $ | 43,054 | $ | 215,270 | $ | 538,175 | 3,973 | 4 |
7,945 | 4 |
15,890 | 4 |
10,593 | 9 |
11,669 | 9 |
$ | 8.57 | $ | 300,000 | ||||||||||||||||||||||||||||||||||
Lourdes G. Weltzien 11 |
11/04/21 | $ | 44,000 | $ | 219,999 | $ | 549,997 | 3,973 | 7,945 | 15,890 | 10,593 | 5 |
11,669 | 6 |
$ | 8.57 | $ | 450,000 | |||||||||||||||||||||||||||||||||||||
Tony Serafini- Lamanna 11 |
11/04/21 | $ | 42,012 | $ | 210,058 | $ | 525,146 | 3,973 | 7,945 | 15,890 | 10,593 | 5 |
11,669 | 6 |
$ | 8.57 | $ | 450,000 | |||||||||||||||||||||||||||||||||||||
Julie Smith |
|
11/04/21 12/06/21 |
$ |
27,450 - |
$ |
137,250 - |
$ |
343,125 - |
|
1,324 - |
|
2,648 - |
|
5,296 - |
|
5,297 5,000 |
5 10 |
|
- - |
|
- - |
$ $ |
150,000 97,750 |
Name | Number of Restricted Stock Units |
Original Grant Date |
Vest Date | ||||||||||||
Mr. Kenny |
|
99,505 56,006 |
|
11/05/19 11/05/20 |
|
10/01/22 11/15/23 |
|||||||||
Mr. Baldasare |
|
1,200 20,534 10,823 |
|
09/16/19 10/31/19 11/05/20 |
|
09/16/22 11/15/22 11/15/23 |
|||||||||
Dr. Weltzien |
|
20,534 12,175 |
|
10/31/19 11/05/20 |
|
11/15/22 11/15/23 |
|||||||||
Mr. Serafini-Lamanna |
|
1,200 12,320 10,823 |
|
09/16/19 10/31/19 11/05/20 |
|
09/16/22 11/15/22 11/15/23 |
Option Awards | Stock Awards | |||||||||||||||||
Name | Number of Securities Underlying Unexercised Options (#) Exercisable |
Number of Securities Underlying Unexercised Options (#) Unexercisable |
Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
Option Exercise Price ($) |
Option Expiration Date |
Number of Shares or Units of Stock That Have Not Vested (#) |
Market Value of Shares or Units of Stock That Have Not Vested ($) |
Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |
Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | |||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | |||||||||
Jack Kenny |
- - - |
66,039 1 83,535 2 82,940 3 |
- - - |
$10.10 $18.48 $18.88 |
11/05/29 11/05/30 11/04/31 |
- - - 99,505 10 56,006 11 56,472 12 |
- - - $3,137,393 $1,765,869 $1,780,562 |
- - - - - - 47,060 16 |
- - - - - - $1,483,802 | |||||||||
Andrew S. Kitzmiller |
- | 5,000 4 |
- | $24.74 | 02/21/32 | - 7,500 13 |
- $ 236,475 |
- - 7,945 16 |
- - $ 250,506 | |||||||||
Bryan T. Baldasare |
11,669 5 |
- | - | $18.88 | 12/31/22 | - | - | - | - | |||||||||
Lourdes G. Weltzien |
10,000 6 2,500 7 - - |
- - 12,107 2 11,669 3 |
- - - - |
$19.66 $14.30 $18.48 $18.88 |
07/01/26 04/24/28 11/05/30 11/04/31 |
- - - - 19,915 14 11,808 11 10,273 12 |
- - - - $ 627,920 $ 372,306 $ 323,908 |
- - - - - - - 7,945 16 |
- - - - - - - $ 250,506 | |||||||||
Tony Serafini- Lamanna |
10,000 8 - - - |
- 4,000 9 12,107 2 11,669 3 |
- - - - |
$14.60 $ 6.97 $18.48 $18.88 |
04/30/28 03/26/30 11/05/30 11/04/31 |
- - - - 12,320 14 10,823 11 10,593 12 |
- - - - $ 388,450 $ 341,249 $ 333,997 |
- - - - - - - 7,945 16 |
- - - - - - - $ 250,506 | |||||||||
Julie Smith |
- | 2,000 9 |
- | $ 6.97 | 03/26/30 | - 6,160 14 5,411 11 5,297 12 5,000 15 |
- $ 194,225 $ 170,609 $ 167,014 $ 157,650 |
- - - - - 2,648 16 |
- - - - - $ 83,491 |
Option Awards |
Stock Awards |
|||||||||||||||
Name | Number of Shares Acquired on Exercise (#) |
Value Realized on Exercise ($) 1 |
Number of Shares Acquired on Vesting (#) |
Value Realized on Vesting ($) 2 |
||||||||||||
(a) | (b) | (c) | (d) | (e) | ||||||||||||
Jack Kenny |
139,603 | $ | 2,568,762 | 50,000 | $ | 1,008,000 | ||||||||||
Andrew S. Kitzmiller |
- | $ | - | - | $ | - | ||||||||||
Bryan T. Baldasare |
12,107 | $ | 100,488 | 55,650 | 3 |
$ | 2,297,247 | |||||||||
Lourdes G. Weltzien |
20,000 | $ | 221,536 | 20,703 | 3 |
$ | 1,235,377 | |||||||||
Tony Serafini-Lamanna |
- | $ | - | 8,700 | 3 |
$ | 189,768 | |||||||||
Julie Smith |
- | $ | - | 5,700 | 3 |
$ | 129,288 |
(i) | Mr. Baldasare: 18,649 units withheld; $509,602 of realized value |
(ii) | Dr. Weltzien: 5,575 units withheld; $111,527 of realized value |
(iii) | Mr. Serafini-Lamanna: 2,589 units withheld; $56,471 of realized value |
(iv) | Ms. Smith: 1,704 units withheld; $38,665 of realized value |
Salary |
$ | 1,421,606 | ||||
Annual Performance Bonus |
1,350,526 | |||||
Total Lump Sum Payment |
$ | 2,772,132 | ||||
Andrew S. Kitzmiller |
Lourdes G. Weltzien |
Tony Serafini- Lamanna |
||||||||||||
Salary |
$ | 760,000 | $ | 799,996 | $ | 763,848 | ||||||||
Annual Performance Bonus |
418,000 | 439,998 | 420,116 | |||||||||||
Earned but Unused Vacation |
12,675 | 20,779 | 22,060 | |||||||||||
Total Lump Sum Payment |
$ | 1,190,675 | $ | 1,260,773 | $ | 1,206,024 | ||||||||
-Base for director service |
$ | 50,000 | ||||
-Additional for Independent Chairperson |
$ | 50,000 | ||||
-AC Chair |
$ | 20,000 | ||||
-AC Member |
$ | 10,000 | ||||
-CC Chair |
$ | 15,000 | ||||
-CC Member |
$ | 7,500 | ||||
-N&CGC Chair |
$ | 13,000 | ||||
-N&CGC Member |
$ | 5,000 |
Name | Fees Earned or Paid in Cash ($) |
Stock Awards ($) 1 |
Option Awards ($) 1 |
Non-Equity Incentive Plan Compensation ($) |
Change in Pension Value and Nonqualified Deferred Compensation Earnings |
All Other Compensation ($) |
Total ($) |
|||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | |||||||||||||||
James M. Anderson |
$ | 72,000 | $ | 62,500 | $ | 62,500 | - | - | - | $ | 197,000 | |||||||||||
Anthony P. Bihl |
$ | 64,625 | $ | 62,500 | $ | 62,500 | - | - | - | $ | 189,625 | |||||||||||
Dwight E. Ellingwood |
$ | 52,500 | $ | 62,500 | $ | 62,500 | - | - | - | $ | 177,500 | |||||||||||
John C. McIlwraith |
$ | 87,750 | $ | 62,500 | $ | 62,500 | - | - | - | $ | 212,750 | |||||||||||
David C. Phillips 2 |
$ | 22,500 | $ | - | $ | - | - | - | - | $ | 22,500 | |||||||||||
John M. Rice |
$ | 51,250 | $ | 62,500 | $ | 62,500 | - | - | - | $ | 176,250 | |||||||||||
Catherine A. Sazdanoff |
$ | 66,125 | $ | 62,500 | $ | 62,500 | - | - | - | $ | 191,125 | |||||||||||
Felicia Williams |
$ | 67,500 | $ | 62,500 | $ | 62,500 | - | - | - | $ | 192,500 |
Plan category |
Number of securities to be issued upon exercise of outstanding options, warrants and rights |
Weighted average exercise price of outstanding options, warrants and rights |
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) | |||
Equity compensation plans approved by security holders |
969 | $ 16.55 | 2,200 | |||
Total (1) |
969 |
$ 16.55 (2) |
2,200 |
(1) | Weighted-average remaining term of 6.19 years for options outstanding. In addition to the shares to be issued upon exercise of outstanding options reflected in the table, approximately 790 shares remain issuable upon the lapsing of currently outstanding restricted stock units, including 101 performance-based restricted stock units projected at the target level (see footnote 2 to the Grants of Plan-Based Awards table on page 22). |
(2) | The weighted average exercise price does not take into account the shares issuable upon vesting of outstanding restricted stock units, deferred stock units and performance units, which have no exercise price. |
Common Stock Beneficially Owned |
||||||||||||||
Name |
Position |
Amount 1 |
Percentage |
|||||||||||
Shareholders |
||||||||||||||
BlackRock, Inc. 2 |
7,405,925 | 16.83% | ||||||||||||
The Vanguard Group, Inc. 3 |
4,876,942 | 11.08% | ||||||||||||
Magnetar Capital LLC 4 |
2,204,418 | 5.01% | ||||||||||||
Directors and Named Executive Officers |
||||||||||||||
Jack Kenny |
Chief Executive Officer and Director |
215,916 | * | |||||||||||
Andrew S. Kitzmiller 5 |
Executive Vice President and Chief Financial Officer | 7,267 | * | |||||||||||
Bryan T. Baldasare 6 |
Former Executive Vice President and Chief Financial Officer | 39,452 | * | |||||||||||
Lourdes G. Weltzien |
Executive Vice President, Life Science |
74,977 | * | |||||||||||
Tony Serafini-Lamanna |
Executive Vice President, Diagnostics | 30,514 | * | |||||||||||
Julie Smith 7 |
Senior Vice President, Controller and Principal Accounting Officer | 42,526 | * | |||||||||||
James M. Anderson |
Director | 120,121 | * | |||||||||||
Anthony P. Bihl |
Director | 31,455 | * | |||||||||||
Dwight E. Ellingwood |
Director | 100,187 | * | |||||||||||
John C. McIlwraith |
Director | 98,121 | * | |||||||||||
John M. Rice |
Director | 59,641 | * | |||||||||||
Catherine A. Sazdanoff |
Director | 94,821 | * | |||||||||||
Felicia Williams |
Director | 59,671 | * | |||||||||||
All Executive Officers and Directors as a Group |
892,691 | 2.00% |
Ernst & Young |
||||||||||
2022 | 2021 | |||||||||
Audit Fees |
$ | 705,000 | $ | 702,500 | ||||||
Audit-Related Fees |
- | - | ||||||||
Tax Fees |
518,071 | 189,150 | ||||||||
$ | 1,223,071 | $ | 891,650 | |||||||
Grant Thornton |
||||||||||
2022 | 2021 | |||||||||
Audit Fees |
$ | - | $ | - | ||||||
Audit-Related Fees |
- | - | ||||||||
Tax Fees |
- | 326,427 | ||||||||
$ | - | $ | 326,427 | |||||||
Exhibit Number |
Description of Exhibit | |
2.2 | Letter Agreement, dated December 9, 2022, by and among Meridian, SD Biosensor, Inc., Columbus Holding Company, and Madeira Acquisition Corp. (Incorporated by reference to Meridian’s Form 8-K filed with the Securities and Exchange Commission (“SEC”) on December 12, 2022) | |
31.1 | Certification of Principal Executive Officer required by Rule 13a-14(a) (Filed herewith) | |
31.2 | Certification of Principal Financial Officer required by Rule 13a-14(a) (Filed herewith) | |
104*** | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
*** | Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability. |
MERIDIAN BIOSCIENCE, INC. |
||
By: /s/ Jack Kenny |
||
Date: January 27, 2023 |
||
Jack Kenny |
||
Chief Executive Officer |
Signature |
Capacity |
Date | ||
/s/ Jack Kenny |
Chief Executive Officer and Director | January 27, 2023 | ||
Jack Kenny | ||||
/s/ Andrew S. Kitzmiller |
Executive Vice President and Chief | January 27, 2023 | ||
Andrew S. Kitzmiller | Financial Officer (Principal Financial Officer) | |||
/s/ Julie Smith |
Senior Vice President and Controller | January 27, 2023 | ||
Julie Smith | (Principal Accounting Officer) | |||
By: /s/ Jack Kenny, Attorney-in-Fact |
Chairman of the Board | January 27, 2023 | ||
John C. McIlwraith | ||||
By: /s/ Jack Kenny, Attorney-in-Fact |
Director | January 27, 2023 | ||
James M. Anderson | ||||
By: /s/ Jack Kenny, Attorney-in-Fact |
Director | January 27, 2023 | ||
Anthony P. Bihl III | ||||
By: /s/ Jack Kenny, Attorney-in-Fact |
Director | January 27, 2023 | ||
Dwight E. Ellingwood | ||||
By: /s/ Jack Kenny, Attorney-in-Fact |
Director | January 27, 2023 | ||
John M. Rice, Jr. | ||||
By: /s/ Jack Kenny, Attorney-in-Fact |
Director | January 27, 2023 | ||
Catherine A. Sazdanoff | ||||
By: /s/ Jack Kenny, Attorney-in-Fact |
Director | January 27, 2023 | ||
Felicia Williams |